Metformin as Anti-Angiogenic Supplemental Treatment for Glioblastoma

Siddharth Shah,Hadeel M. Mansour,Tania M. Aguilar,Brandon Lucke-Wold
DOI: https://doi.org/10.3390/ijms25115694
IF: 5.6
2024-05-24
International Journal of Molecular Sciences
Abstract:According to the WHO 2016 classification, glioblastoma is the most prevalent primary tumor in the adult central nervous system (CNS) and is categorized as grade IV. With an average lifespan of about 15 months from diagnosis, glioblastoma has a poor prognosis and presents a significant treatment challenge. Aberrant angiogenesis, which promotes tumor neovascularization and is a prospective target for molecular target treatment, is one of its unique and aggressive characteristics. Recently, the existence of glioma stem cells (GSCs) within the tumor, which are tolerant to chemotherapy and radiation, has been linked to the highly aggressive form of glioblastoma. Anti-angiogenic medications have not significantly improved overall survival (OS), despite various preclinical investigations and clinical trials demonstrating encouraging results. This suggests the need to discover new treatment options. Glioblastoma is one of the numerous cancers for which metformin, an anti-hyperglycemic medication belonging to the Biguanides family, is used as first-line therapy for type 2 diabetes mellitus (T2DM), and it has shown both in vitro and in vivo anti-tumoral activity. Based on these findings, the medication has been repurposed, which has shown the inhibition of many oncopromoter mechanisms and, as a result, identified the molecular pathways involved. Metformin inhibits cancer cell growth by blocking the LKB1/AMPK/mTOR/S6K1 pathway, leading to selective cell death in GSCs and inhibiting the proliferation of CD133+ cells. It has minimal impact on differentiated glioblastoma cells and normal human stem cells. The systematic retrieval of information was performed on PubMed. A total of 106 articles were found in a search on metformin for glioblastoma. Out of these six articles were Meta-analyses, Randomized Controlled Trials, clinical trials, and Systematic Reviews. The rest were Literature review articles. These articles were from the years 2011 to 2024. Appropriate studies were isolated, and important information from each of them was understood and entered into a database from which the information was used in this article. The clinical trials on metformin use in the treatment of glioblastoma were searched on clinicaltrials.gov. In this article, we examine and evaluate metformin's possible anti-tumoral effects on glioblastoma, determining whether or not it may appropriately function as an anti-angiogenic substance and be safely added to the treatment and management of glioblastoma patients.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the potential role of metformin as an anti - angiogenic complementary treatment in glioblastoma (GBM). Specifically, the paper focuses on the following points: 1. **Treatment challenges of glioblastoma**: Glioblastoma is a highly malignant brain tumor with a high recurrence rate and poor prognosis. Although existing treatment methods (such as surgery, radiotherapy, and chemotherapy) have made certain progress, the survival time of patients is still very limited, with an average survival time of only about 15 months. Therefore, finding new treatment strategies to improve the prognosis of patients is the focus of current research. 2. **Antitumor potential of metformin**: Metformin is a commonly used hypoglycemic drug. Recent studies have found that it exhibits antitumor activity in a variety of cancers. The paper details the mechanism by which metformin inhibits the growth and proliferation of cancer cells by activating the AMPK pathway, as well as its specific killing effect on glioblastoma stem cells (GSCs). 3. **Combined application of metformin and existing treatments**: The paper evaluates the efficacy and safety of the combined use of metformin and standard treatment drugs (such as temozolomide). Studies have shown that metformin can enhance the cytotoxicity of temozolomide and improve the treatment effect, especially for glioblastoma patients with MGMT promoter methylation. 4. **Current status and prospects of clinical trials**: The paper summarizes a number of clinical trials that are currently ongoing or have been completed, which aim to evaluate the application of metformin in the treatment of glioblastoma. Preliminary trial results show that metformin can prolong the progression - free survival time and overall survival time of patients in some cases, but more data are needed to verify its long - term efficacy and safety. In summary, the main purpose of this paper is to evaluate the potential value of metformin as an anti - angiogenic complementary treatment in glioblastoma and to explore the feasibility and effectiveness of its combined application with existing treatment methods.